Subscribe
pills-istock-525984851
sprng23 / iStockphoto.com
23 March 2017Americas

PTAB upholds Biogen’s MS drug patent

A Biogen patent covering the drug Tecfidera (dimethyl fumarate) has been  upheld by the Patent Trial and Appeal Board (PTAB), after a challenge from Kyle Bass’s Coalition for Affordable Drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Biogen loses another battle over MS drug patent
21 September 2020   In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.


Editor's picks

Explainer: ARIPO’s role in Plant Variety Protection
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025

Editor's picks

Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025

More on this story

Biotechnology
Biogen loses another battle over MS drug patent
21 September 2020   In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.

More on this story

Biotechnology
Biogen loses another battle over MS drug patent
21 September 2020   In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.

More features

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Explainer: ARIPO’s role in Plant Variety Protection
J&J sues over schizophrenia drug generic following patent victory
WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era
Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids